The prognostic value of NLRP1/NLRP3 and its relationship with immune infiltration in human gastric cancer

Abstract

Background: Inflammasomes are related to tumorigenesis and immune-regulation. Here, we investigated the prognostic value of the NLR family pyrin domain containing (NLRP) 1/NLRP3 inflammasome and its potential mechanisms in immune-regulation in gastric cancer (GC). Methods: We analyzed the differential expression of NLRP1/NLRP3 between tumor and normal tissues using the Oncomine and Tumor Immune Estimate Resource (TIMER) databases. Immunohistochemistry and western blotting were used to detect NLRP1/NLRP3 protein expression in GC tissues. Correlations between NLRP1/NLRP3 expression levels and patient survival were analyzed using Kaplan-Meier survival curves. The relationships of NLRP1/NLRP3 expression and tumor-infiltrating immune cells/marker genes were assessed using the TIMER database. NLRP1/NLRP3 and immune checkpoint gene correlations were verified by singlegene co-expression analyses, and tumor immune-related pathways involving NLRP1/NLRP3 were analyzed using gene set enrichment analysis (GSEA). Results: Elevated NLRP1/NLRP3 expression was significantly correlated with lymph node metastasis, poor survival, immune-infiltrating cell abundances, and immune cell markers. NLRP3 showed stronger correlations with immune infiltration and the prognosis of gastric cancer. NLRP1 and NLRP3 might be involved in the same tumor immune-related pathways. Thus, high NLRP1/NLRP3 expression promotes immune cell infiltration and poor prognosis in GC. NLRP1/NLRP3, particularly NLRP3, may have important roles in immune infiltration and may serve as a prognostic biomarker for GC. Conclusions: NLRP1/NLRP3, particularly NLRP3, may have important roles in immune infiltration and may serve as a prognostic biomarker for GC.

The NLRP1 inflammasome emerges as a promising therapeutic target and prognostic biomarker across multiple cancer types: A comprehensive pan-cancer analysis

“…Furthermore, the downregulation of NLRP1 is correlated with unfavorable DFS in CHOL. Several studies have explored the potential of NLRP1 as a prognostic biomarker in various cancers, including lung adenocarcinoma [39,40,44], gastric cancer [45], prostate cancer [43], pancreatic cancer [46,47], head and neck squamous cell carcinoma [48], and laryngeal carcinoma [49]. Shen et al con rmed that decreased expression of NLRP1 was signi cantly associated with a poor prognosis of LUAD [41].…”

Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes

“…This suggests their potential involvement in the activity of antigen-presenting cells, thereby indicating that these antigens may be presented to T cells by APCs and recognized by them [ 47 ]. Since these genes are involved in apoptosis, which is a form of programmed cell death that can lead to cellular rupture and demise, we hypothesize that these genes may initiate the process of apoptosis in tumor cells, consequently leading to cell death [ 42 , 48 ]. The survival analysis results verified that high levels of these genes predicted a better prognosis.…”

Identification of a common therapeutic objective in both rheumatoid arthritis and the microenvironment of gastric tumors

“…2,3 Real-world studies also show that effectively reducing NLRP1/NLRP3 can reduce gastric cancer progression. 4 However, more studies are needed to decipher the detailed mechanism of microenvironment formation during TTC4 processing.…”